Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France
Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France
The purpose of this study is to respond to The French Health Authority which has requested
 BMS France and Astra Zeneca (AZ) France to set-up a long-term cohort study in a
 representative sample of French Type 2 Diabetes mellitus (T2D) patients treated with
 Saxagliptin to generate real world data on drug utilization, joint population, non
 comparative effectiveness and safety
Time Perspective: Ambispective cohort follow by a 18 to 24 month follow up period,
 Retrospective follow by Prospective.
Inclusion Criteria:

 -  Registry

 -  Patient ≥ 18 years old

 -  Patient with T2D

 -  Ambispective Cohort

 -  Patient ≥ 18 years old

 -  Patient with T2D

 -  Patient initiated with Saxagliptin in the last 6 months before the inclusion or
 day of inclusion visit (whatever his/her ongoing hypoglycaemic treatment)

 -  Patient agreeing to participate, and not yet enrolled by another physician

 Exclusion Criteria:

 -  Patient participating in a clinical trial